Plasbumin United States
United States  |   For US Healthcare Professionals Only

 Advanced Search

Print this Page
Commitment to Safety. Screening Method

With the acquisition of a large, national network of Plasma Collection Centers and a commitment to increasing production, Talecris is prepared to meet growing demand.

Each plasma donation center is inspected three to six times each year by various Federal and State regulatory agencies and organizations, as well as by Talecris Biotherapeutics' quality assurance department.

First-time Donor
Every first-time donor undergoes an extensive screening program:

Medical Exam
Medical History
Check against the National Donor Deferral Registry (NDDR)
Two sequential screening and serological viral tests are conducted within a six-month period:

Human immunodeficiency virus (HIV)
Hepatitis B (HBV)
Hepatitis C (HCV)

Plasma donations are held until the test results are completed.

Repeat Donations Required
For additional safety, Talecris Biotherapeutics holds a donor's plasma until the donor returns for a second donation.

If a donor does not return to the center in 60 days, the donor's plasma is destroyed. This repeat donation requirement has increased plasma safety dramatically.1,2
Virus Reduction
Prion Clearance
Talecris Research

References

1.   Remington KM, Petteway SR Jr. Comprehensive pathogen safety management for Plasbumin. Pediatr Crit Care Med. 2001;2(suppl):S23-S27.
2.   Council of Europe, Public Health Committee. Human Plasma for Fractionation.1998. Resolution AP-CSP (98) 11.
Plasbumin® Home  |   Healthcare Professionals  |   Excipient Customers  |   Patients
Important Safety Information  |   Prescribing Information  |   Site Map  |   Glossary



Talecris Biotherapeutics
Contact Talecris    General Conditions of Use    Privacy Statement   
This site is intended for US residents only. Non-US residents can go to www.Talecris.com.
© 2009 Talecris Biotherapeutics


 

 

 

 

 

 

Update Flash